The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial
Abstract
BACKGROUND AND AIMS: Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis. Additionally, Asacol dosed at 2.4 g/day has been proved to be more effective than 1.6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown. METHODS: A randomized, double-blind, controlled trial (ASCEND II) was conducted to evaluate the efficacy of 4.8 g/day of mesalamine in adults with active ulcerative colitis. Three hundred eighty-six patients with mild to moderate ulcerative colitis were randomized for treatment with mesalamine 2.4 g/day (400 mg tablet) or 4.8 g/day (800 mg tablet) for 6 wk. The primary efficacy population was 268 patients with moderately active ulcerative colitis treated with 2.4 g/day (n = 139) or 4.8 g/day (n = 129). The primary endpoint was the proportion of patients in each treatment group that achieved overall improvement ("treatment success," defined as either complete remission or a clinical response to therapy) from baseline at week 6. RESULTS: Seventy-two percent of patients receiving 4.8 g/day of mesalamine for moderate ulcerative colitis (89/124 patients) achieved treatment success at week 6, compared with 59% of those who received 2.4 g/day (77/130 patients) (p= 0.036). Both regimens were well tolerated. Adverse events and clinically significant changes in laboratory results were similar in both treatment groups. CONCLUSIONS: Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Self-citationMedication nonadherence and the outcomes of patients with quiescent ulcerative colitis
Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01383-9 · Cited by 569
Self-citationPrevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
Kane, S. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)03245-2 · Cited by 429
(2006) · Operative Pediatric Surgery 6Ed · doi:10.1201/b13237-67 · Cited by 341
Sandborn, W. J., & Hanauer, S. B. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01408.x · Cited by 247
Self-citationSutherland, L. R., May, G. R., & Shaffer, E. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00009 · Cited by 230
Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis
Loftus, E. V., Kane, S. V., & Bjorkman, D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.0269-2813.2004.01827.x · Cited by 184
An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis
Hanauer, S. B., Sninsky, C. A., Robinson, M., Powers, B. J., McHattie, J. D., Mayle, J. E., Elson, C. O., DeMicco, M. P., Butt, J. H., Pruitt, R. E., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-2-199601150-00003 · Cited by 155
Self-citation
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Self-citationInflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Self-citationDignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Metadata
- Authors
- Hanauer, S. B., Sandborn, W. J., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F.
- Venue
- The American Journal of Gastroenterology
- Published
- 2005-11
- Volume
- 100
- Issue
- 11
- Pages
- 2478-2485
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2056461886
- Cited by
- 322
- References
- 13
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial. https://app.cochat.ai/papers/10.1111/j.1572-0241.2005.00248.x
- The paper
- Hanauer, S. B., Sandborn, W. J., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F. (2005). Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2005.00248.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.